Sugi Predict

Sugi Predict / Targets / CHRNA10

CHRNA10

Neuronal acetylcholine receptor subunit alpha-10 · Q9GZZ6 · CHRNA10 on Sugi Atlas →

10,495 patent compounds predicted against CHRNA10, 6,627 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Iodide Iodide (SCHEMBL1019297) 0.58 9/20
SCHEMBL584752 SCHEMBL584752 0.43 7/20
SCHEMBL80826 SCHEMBL80826 0.63 6/20
Stilonium Stilonium (SCHEMBL26104) 1.00 5/20
Stilonium Stilonium (SCHEMBL26105) 1.00 5/20
SCHEMBL1618632 SCHEMBL1618632 0.67 5/20
Iodide Iodide (SCHEMBL1320371) 0.62 5/20
SCHEMBL1321703 SCHEMBL1321703 0.59 5/20
SCHEMBL1663972 SCHEMBL1663972 0.58 5/20
SCHEMBL81218 SCHEMBL81218 0.58 5/20
SCHEMBL81293 SCHEMBL81293 0.57 5/20
SCHEMBL123740 SCHEMBL123740 0.55 5/20
SCHEMBL1226431 SCHEMBL1226431 0.52 5/20
SCHEMBL1126920 SCHEMBL1126920 0.50 5/20
SCHEMBL1535035 SCHEMBL1535035 0.45 5/20
SCHEMBL677293 SCHEMBL677293 0.45 5/20
SCHEMBL677083 SCHEMBL677083 0.44 5/20
SCHEMBL677499 SCHEMBL677499 0.44 5/20
SCHEMBL123118 SCHEMBL123118 0.52 4/20
Bromide Bromide (SCHEMBL1087062) 0.51 4/20

Clinical trials — most relevant to CHRNA10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Postoperative Sugammadex After COVID-19 PHASE4UNKNOWN
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
Nicotinic Receptor Augmentation of SSRI Antidepressants PHASE2COMPLETED
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism PHASE1/PHASE2COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition PHASE2RECRUITING
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease PHASE1/PHASE2RECRUITING
Nicotine Treatment of Cognitive Decline in Down Syndrome PHASE1/PHASE2COMPLETED
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine PHASE1WITHDRAWN
Gene Therapy for Alzheimer's Disease Clinical Trial PHASE1COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia nanCOMPLETED
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome. nanRECRUITING
Brain Imaging in Alzheimer's Disease nanCOMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients nanCOMPLETED
Nicotinic Receptor Levels After Stopping Smoking nanCOMPLETED
Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers nanCOMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNA10 binder may also engage these)

ProteinNameSimilarity
Q9JLB5 — 0.998 Q9JLB5 →
CHRNB1 Acetylcholine receptor subunit beta 0.947 landscape →
P13536 — 0.945 P13536 →
P04758 — 0.940 P04758 →
P04760 — 0.939 P04760 →
P25109 — 0.939 P25109 →
CHRNG Acetylcholine receptor subunit gamma 0.939 landscape →
CHRNE Acetylcholine receptor subunit epsilon 0.938 landscape →
P02715 — 0.936 P02715 →
P18916 — 0.934 P18916 →
Q9UJ96 — 0.934 Q9UJ96 →
P09690 — 0.934 P09690 →
Q8VHN2 — 0.932 Q8VHN2 →
GRIN3B Glutamate receptor ionotropic, NMDA 3B (GluN3 0.932 landscape →
Q9QYU3 — 0.931 Q9QYU3 →
Q91ZU9 — 0.930 Q91ZU9 →
GRM6 Metabotropic glutamate receptor 6 0.930 landscape →
Q5NCH9 — 0.930 Q5NCH9 →
P35349 — 0.930 P35349 →
Q9I8C7 — 0.929 Q9I8C7 →
P09660 — 0.928 P09660 →
Q863I4 — 0.927 Q863I4 →
P20782 — 0.926 P20782 →
MCOLN1 Mucolipin-1 0.923 landscape →
Q60HE8 — 0.923 Q60HE8 →
Q9Y644 — 0.920 Q9Y644 →
TRPM5 Transient receptor potential cation channel subfamily M member 5 0.920 landscape →
Q03391 — 0.918 Q03391 →
D4ABX8 — 0.917 D4ABX8 →
AVPR2 Vasopressin V2 receptor 0.917 landscape →